Abstract

The TAR DNA Binding Protein 43 (TDP-43) has been implicated in the pathogenesis of human neurodegenerative diseases and exhibits hallmark neuropathology in amyotrophic lateral sclerosis (ALS). Here, we explore its tractability as a plasma biomarker of disease and describe its localization and possible functions in the cytosol of platelets. Novel TDP-43 immunoassays were developed on three different technical platforms and qualified for specificity, signal-to-noise ratio, detection range, variation, spike recovery and dilution linearity in human plasma samples. Surprisingly, implementation of these assays demonstrated that biobank-archived plasma samples yielded considerable heterogeneity in TDP-43 levels. Importantly, subsequent investigation attributed these differences to variable platelet recovery. Fractionations of fresh blood revealed that ≥ 95% of the TDP-43 in platelet-containing plasma was compartmentalized within the platelet cytosol. We reasoned that this highly concentrated source of TDP-43 comprised an interesting substrate for biochemical analyses. Additional characterization of platelets revealed the presence of the disease-associated phosphoserine 409/410 TDP-43 proteoform and many neuron- and astrocyte-expressed TDP-43 mRNA targets. Considering these striking similarities, we propose that TDP-43 may serve analogous functional roles in platelets and synapses, and that the study of platelet TDP-43 might provide a window into disease-related TDP-43 dyshomeostasis in the central nervous system.

Details

Title
Location and function of TDP-43 in platelets, alterations in neurodegenerative diseases and arising considerations for current plasma biobank protocols
Author
Luthi-Carter, Ruth 1 ; Cappelli, Sara 2 ; Le Roux-Bourdieu, Morgan 1 ; Tentillier, Noemie 1 ; Quinn, James P. 3 ; Petrozziello, Tiziana 4 ; Gopalakrishnan, Lathika 5 ; Sethi, Purva 6 ; Choudhary, Himanshi 2 ; Bartolini, Giorgia 1 ; Gebara, Elias 1 ; Stuani, Cristiana 2 ; Font, Laure 1 ; An, Jiyan 5 ; Ortega, Vanessa 5 ; Sage, Jessica 7 ; Kosa, Edina 6 ; Trombetta, Bianca A. 8 ; Simeone, Roberto 9 ; Seredenina, Tamara 1 ; Afroz, Tariq 1 ; Berry, James D. 10 ; Arnold, Steven E. 11 ; Carlyle, Becky C. 12 ; Adolfsson, Oskar 1 ; Sadri-Vakili, Ghazaleh 13 ; Buratti, Emanuele 2 ; Bowser, Robert 5 ; Agbas, Abdulbaki 6 

 AC Immune, SA (ACIU), Lausanne, Switzerland (GRID:grid.476060.3) (ISNI:0000 0004 7702 9629) 
 International Centre for Genetic Engineering and Biotechnology, Trieste, Italy (GRID:grid.425196.d) (ISNI:0000 0004 1759 4810) 
 Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts Alzheimer’s Disease Research Center (ADRC), Charlestown, USA (GRID:grid.32224.35); MassGeneral Institute for Neurodegenerative Disease, Charlestown, USA (GRID:grid.32224.35); Eisai US, Cambridge, USA (GRID:grid.418767.b) (ISNI:0000 0004 0599 8842) 
 Sean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
 Barrow Neurological Institute, Department of Translational Neuroscience, Phoenix, USA (GRID:grid.427785.b) (ISNI:0000 0001 0664 3531) 
 Kansas City University, Kansas City, USA (GRID:grid.258405.e) (ISNI:0000 0004 0539 5056) 
 Kansas City University, Kansas City, USA (GRID:grid.258405.e) (ISNI:0000 0004 0539 5056); Boehringer Ingelheim Vetmedica, St Joseph, USA (GRID:grid.418412.a) (ISNI:0000 0001 1312 9717) 
 Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts Alzheimer’s Disease Research Center (ADRC), Charlestown, USA (GRID:grid.32224.35) 
 Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Dipartimento di Medicina Trasfusionale Giuliano-Isontina, Trieste, Italy (GRID:grid.32224.35) 
10  Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Sean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Neurological Clinical Research Institute, Boston, USA (GRID:grid.32224.35) 
11  Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts Alzheimer’s Disease Research Center (ADRC), Charlestown, USA (GRID:grid.32224.35); MassGeneral Institute for Neurodegenerative Disease, Charlestown, USA (GRID:grid.32224.35); Sean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
12  Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); Massachusetts Alzheimer’s Disease Research Center (ADRC), Charlestown, USA (GRID:grid.32224.35); University of Oxford, Department of Physiology, Anatomy and Genetics and Kavli Institute for Nanoscience Discovery, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
13  Massachusetts General Hospital Department of Neurology, Charlestown, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924); MassGeneral Institute for Neurodegenerative Disease, Charlestown, USA (GRID:grid.32224.35); Sean M. Healey and AMG Center for ALS at MassGeneral, Massachusetts General Hospital, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924) 
Pages
21837
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3106554510
Copyright
© The Author(s) 2024. corrected publication 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.